PEspeaks

Feb 23, 2012
Pharmaceutical Executive
So far, the creative approaches industry has taken to develop tamper-resistant and abuse-deterrent opioid drugs have been largely matched by the ingenuity of those users who manage to tamper with and abuse those same formulations.
Feb 23, 2012
Pharmaceutical Executive
Publicis Healthcare continues its expansion into Asia with this week’s announcement of its acquisition of U-Link Business Solutions (UBS), one of China’s leading agencies specializing in healthcare communications.
Feb 21, 2012
Pharmaceutical Executive
Whichever way you look at it, 2012 will be a dramatic year for Servier. The French company has a number of collaborations that could lead to a new generation of products, but any positive news from these developments is likely to be overshadowed by the ongoing safety scandal of its diabetes treatment Mediator (benfluorex hydrochloride).
Feb 18, 2012
Pharmaceutical Executive
A new collaboration will move FDA closer to predicting adverse events – before they happen – as part of the regulatory process
Feb 16, 2012
Pharmaceutical Executive
By admin
As health reforms sweep in major changes to our nation’s healthcare system, patient assistance and access programs (PAPs) are rapidly evolving to assess and meet new needs.
Feb 15, 2012
Pharmaceutical Executive
As the perceived urgency for transparency and compliance in global pharma grows ever stronger, the ‘Sunshine provisions’ of the US’s Patient Protection and Affordable Care Act (ACA) seem increasingly aptly named
Feb 15, 2012
Pharmaceutical Executive
As the hurdles to successful commercialization of new medicines continue to mount, the ability to find and exploit cost efficiencies in the development process has become a critical source of competitive advantage.
Feb 13, 2012
Pharmaceutical Executive
William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.
Feb 13, 2012
Pharmaceutical Executive
All-told the Mayo Clinic’s recent pilot study on clinical trial patient recruitment using social media and online networks not only helped researchers assemble large and demographically diverse patient groups more quickly, but also less expensively than they could through other means
Feb 10, 2012
Pharmaceutical Executive
native1_300x100
lorem ipsum